Quarterly report pursuant to Section 13 or 15(d)

11. SEGMENT INFORMATION (Tables)

v3.8.0.1
11. SEGMENT INFORMATION (Tables)
9 Months Ended
Sep. 30, 2017
Segment Reporting [Abstract]  
Schedule Of Segment Reporting Information
  Consumer Products Segment     Specialty Pharmaceutical Segment     Consolidated Totals  
Three Months Ended                        
September 30, 2017:                        
Product sales, net   $ 5,591,210     $     $ 5,591,210  
Gross profit     3,997,649             3,997,649  
Gain on change in derivative liability     10,987             10,987  
Royalty buy-out                  
Selling, general and administrative     (4,259,725 )     (51,353 )     (4,311,078 )
Research and development     (76,520 )     (102,818 )     (179,338 )
Operating loss   $ (327,609 )   $ (154,171 )   $ (481,780 )
                         
Three Months Ended                        
September 30, 2016:                        
Product sales, net   $ 2,939,997     $     $ 2,939,997  
Gross profit     1,888,949             1,888,949  
Selling, general and administrative     (2,952,533 )     (119,908 )     (3,072,441 )
Research and development     (292,738 )     (103,500 )     (396,238 )
Operating loss   $ (1,356,322 )   $ (223,408 )   $ (1,579,730 )
                         
Nine Months Ended                        
September 30, 2017:                        
Product sales, net   $ 13,437,233     $     $ 13,437,233  
Gross profit     9,275,111             9,275,111  
Gain on change in derivative liability     248,875             248,875  
Royalty buy-out           (2,432,000 )     (2,432,000 )
Selling, general and administrative     (11,312,687 )     (200,873 )     (11,513,560 )
Research and development     (181,509 )     (392,192 )     (573,701 )
Operating loss   $ (1,970,210 )   $ (3,025,065 )   $ (4,995,275 )
                         
Nine Months Ended                        
September 30, 2016:                        
Product sales, net   $ 7,850,430     $     $ 7,850,430  
Gross profit     5,178,911             5,178,911  
Selling, general and administrative     (8,904,694 )     (242,717 )     (9,147,411 )
Research and development     (658,817 )     (220,781 )     (879,598 )
Operating loss   $ (4,384,600 )   $ (463,498 )   $ (4,848,098 )